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Abstract
Objectives: The purpose of this study was to assess in vivo the reproducibility of tissue characterization
using spectral analysis of intravascular ultrasound (IVUS) radiofrequency data (IVUS-VH). Back-
ground: Despite the need for reproducibility data to design longitudinal studies, such information remains
unexplored. Methods and results: IVUS-VH (Volcano Corp., Rancho Cordova, USA) was performed in
patients referred for elective percutaneous intervention and in whom a non-intervened vessel was judged
suitable for a safe IVUS interrogation. The IVUS catheters used were commercially available catheters
(20 MHz, Volcano Corp., Rancho Cordova, USA). Following IVUS-VH acquisition, and after the dis-
engagement and re-engagement of the guiding catheter, an additional acquisition was performed using a
new IVUS catheter. Fifteen patients with 16 non-significant lesions were assessed by 2 independent
observers. The relative inter-catheter differences regarding geometrical measurements were negligible for
both observers. The inter-catheter relative difference in plaque cross-sectional area (CSA) was 3.2% for
observer 1 and 0.5% for observer 2. The limits of agreement for (observer 1 measurements) lumen, vessel,
plaque and plaque burden measurements were 0.82, )1.10 mm2; 0.80, )0.66 mm2; 1.08, )0.66 mm2; and
5.83, )3.89%; respectively. Limits of agreement for calcium, fibrous, fibrolipidic and necrotic core CSA
measurements were 0.22, )0.25 mm2; 1.02, )0.71 mm2; 0.61, )0.65 mm2; and 0.43, )0.38 mm2 respectively.
Regarding the inter-observer agreement, the limits of agreement for lumen, vessel, plaque and plaque
burden measurements were 2.61, )2.09 mm2; 2.20–3.03 mm2; 1.70, )3.04 mm2; and 9.16, )16.41%;
respectively, and for calcium, fibrous, fibrolipidic and necrotic core measurements of 0.08, )0.09 mm2; 0.89,
)1.28 mm2; 0.74, )1.06 mm2; and 0.16, )0.20 mm2; respectively. Conclusions: The present study demon-
strates that the geometrical and compositional output of IVUS-VH is acceptably reproducible.
Introduction
Intravascular ultrasound (IVUS) imaging has been
shown to provide safe, accurate, real-time, tomo-
graphic measurements of coronary vessels in vivo
[1–4]. Over the past decade, IVUS has been used to
describe the extent, severity, distribution, and
morphology of coronary atherosclerosis [5–7].
Furthermore, several studies have evaluated the
temporal effect of conventional and novel medical
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therapies on plaque progression by means of IVUS
[8–10].
Since the fate of coronary atherosclerotic plaques
has been related to their histological composition
[11], precise in-vivo tissue characterization could
provide important additional information and be-
come a target for future drug therapy studies.
In-vitro studies have shown that visual inter-
pretation of IVUS gray-scale images for plaque
characterization is imprecise, in particular when
assessing heterogeneous, lipid-rich plaques [12].
This has lead investigators to explore the radio-
frequency data analysis, a potential source for
in-vivo tissue characterization. Indeed, a recent
ex-vivo study on explanted coronary segments
showed that plaque characterization using spectral
analysis of IVUS radiofrequency data (IVUS-VH)
was feasible and provided a high predictive accu-
racy to estimate the composition of atherosclerotic
plaques [13]. Several in-vivo studies have been
conducted thereafter using this approach [14–17].
Nevertheless, although prior knowledge about the
reproducibility of measurements are essential for
the internal validity of any study using this tech-
nique, to date, only indirect evidence on the
reproducibility of the technique is available [18].
Accordingly, we sought to study the inter-observer
and inter-catheter agreement of IVUS-VH mea-
surements at a single time-point.
Methods
Patient population
This was a single-center prospective, investigators-
driven study that sought to explore in vivo the
reproducibility of spectral analysis of IVUS ra-
diofrequency data (IVUS-VH, Volcano Corp.,
Rancho Cordova, USA). The study population
consisted of consecutive patients that were referred
for elective percutaneous intervention and in
whom a non-intervened vessel was judged suitable
for a safe IVUS interrogation of a vessel segment
of at least 30 mm.
Exclusion criteria included the presence of severe
calcification, vessel tortuosity, and haemodynamic
instability. The study protocol was approved by the
institutional ethics committee and a written in-
formed consent was obtained from all patients.
IVUS-VH
IVUS-VH evaluates different spectral parameters
of the radiofrequency data (Y-intercept, minimum
power, maximum power, mid-band power, fre-
quency at minimum power, frequency at maxi-
mum power, slope, etc.) to construct tissue maps
that classify plaque into four major components.
In preliminary in vitro studies, four histological
plaque components (fibrous, fibrolipidic, necrotic
core and calcium) were correlated with a specific
spectrum of the radiofrequency signal [13]. These
different plaque components were assigned color
codes. Calcified, fibrous, fibrolipidic and necrotic
core regions were labeled white, green, greenish-
yellow and red respectively.
IVUS-VH acquisition
The IVUS catheters used were commercially
available phased array catheters (Eagle Eye
GoldTM 2.9 F 20 MHz, Volcano Corp., Rancho
Cordova, USA). The catheter probe was advanced
at least 10 mm distal to a clearly visible side-branch
and angiographic cine runs, before and during
contrast injection, were performed to define the
position of the IVUS catheter before the pullback
was started. Using an automated pullback device,
the transducer was withdrawn at a continuous
speed of 0.5 mm/s. IVUS-VH acquisition was
ECG-gated and acquired using a dedicated console
(Volcano Corporation, Rancho Cordova, USA).
IVUS-VH data was acquired after intra-coronary
administration of isosorbide dinitrate and data was
stored on DVD. Subsequently, and after the dis-
engagement and re-engagement of the guiding
catheter, the same procedure was performed using
a new catheter (Eagle Eye GoldTM 2.9 F 20 MHz,
Volcano Corp., Rancho Cordova, USA) and with
the same side-branches as landmarks.
IVUS-VH analysis
IVUS-VH analysis was performed by an indepen-
dent core laboratory (Cardialysis BV, Rotterdam,
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The Netherlands) using a semi-automatic contour
detection software (IVUSLab 4.4, Volcano Corp.,
Rancho Cordova, USA). A region of interest
(ROI) was identified using the inner side of two
clear side-branches as reference and avoiding the
presence of large side-branches within the ROI.
Subsequently, the same ROI was identified in the
other catheter’s acquisition using side-by-side
longitudinal and cross-sectional, contour-free
views.
Contour detection of the lumen and the media-
adventitia interface was performed by 2 indepen-
dent experienced IVUS analysts. The same 2 IVUS
analysts re-analyzed the same cases, leading to the
possibility of multiple comparisons: 2 sets (observ-
ers 1 and 2) of intra-catheter agreement, and 1 set of
inter-observer agreement [observer 1 (catheters 1
and 2) vs. observer 2 (catheters 1 and 2)].
The contours of the external elastic membrane
(EEM) and the lumen–intima interface enclosed
an area that was defined as the coronary plaque
plus media area. Geometrical and compositional
data were obtained for each cross-sectional area
(CSA) and an average was calculated for each
ROI. Plaque burden was calculated as [(EEMarea
 Lumenarea=EEMareaÞ  100]. The lumen and
vessel eccentricity indexes were calculated dividing
the minimum (lumen and vessel, respectively)
diameter by the maximum diameter, whereas the
plaque eccentricity index was calculated dividing
the minimum plaque thickness by the maximum
plaque thickness.
Statistical analysis
Discrete variables are presented as counts and
percentages. Continuous variables are presented as
means ± SD. The inter-observer and inter-cathe-
ter agreement were assessed using Bland–Altman
plots [19]. This method plots the mean against the
difference in measurements. Limits of agreement
were determined by adding two standard devia-
tions to the mean difference for the upper limit and
by substracting two standard deviations from the
mean difference for the lower limit. A two-sided
p value of less than 0.05 indicated statistical
significance.
Results
Fifteen consecutive patients with 16 non-signifi-
cant lesions were included in the study. Baseline
characteristics of the patients included are depicted
in Table 1. The study vessel was the left anterior
descending in 9 patients (60.0%), the left circum-
flex in 5 (33.3%), and the right coronary artery in 1
patient (6.7%). There were no peri-procedural
complications.
Inter-catheter agreement
The studied length determined by landmarks was
19.71±10.5 mm for catheter 1 and 21.01±11.1
mm for catheter 2 (p=0.32). Geometrical and
compositional data of matched ROIs interrogated
with IVUS-VH using 2 subsequent 20 MHz cath-
eters are extensively depicted in Tables 2 and 3.
The relative inter-catheter differences regarding
geometrical measurements were negligible for both
observers. Of note, the inter-catheter relative dif-
ference in plaque CSA was 3.2% for observer 1
and 0.5% for observer 2. Only other less common
indirect measurements such as plaque eccentricity
and plaque minimal thickness showed relative
differences >5%. Compositional measurements
showed higher relative differences, although not
Table 1. Study population (n=15).
n (%)
Age (years±SD) 63.1±8.6
Male sex 8 (53.3)
Diabetes 2 (13.3)
Hypertension 11 (73.3)
Current smoking 1 (6.7)
Previous smoking 5 (33.3)
Hypercholesterolemia 8 (53.3)
Family history of coronary disease 9 (60.0)
Lipid lowering agents 11 (73.3)
Clinical presentation
Stable angina 14 (93.3)
Unstable angina 1 (6.7)
Study vessel
Left anterior descending 9 (60.0)
Left circumflex 5 (33.3)
Right coronary artery 1 (6.7)
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exceeding 10%, except from calcium (11%) for
observer 1 and fibrolipidic tissue (13%) for
observer 2 (Table 3). Indeed, Bland–Altman plots
showed a good inter-catheter agreement for
geometrical (Figure 1) and compositional (Fig-
ure 2) measurements. The limits of agreement for
(observer 1 measurements) lumen, vessel, plaque
and plaque burden measurements were 0.82,
)1.10 mm2; 0.80, )0.66 mm2; 1.08, )0.66 mm2;
and 5.83, )3.89%; respectively. Limits of agree-
ment for calcium, fibrous, fibrolipidic and necrotic
core CSA measurements were 0.22, )0.25 mm2;
1.02, )0.71 mm2; 0.61, )0.65 mm2; and 0.43,
)0.38 mm2 respectively.
Inter-observer agreement
For the assessment of the inter-observer agree-
ment, a comparison between the same matched
cross-sections (653 frames for catheter 1 and 663
frames for catheter 2) were analyzed by 2 inde-
pendent observers. These 2 datasets were merged
resulting in a paired inter-observer agreement
evaluation of 1316 frames.
Inter-observer differences were larger than the
inter-catheter measurements (performed by the
same observer). This was particularly noticed in
indirect measurements such as plaque CSA (10%),
plaque minimal thickness (53%) and plaque
Table 2. Mean CSA geometrical measurements of matched ROI with two subsequent 20 MHz IVUS imaging catheters (n:16).
Catheter 1 Catheter 2 Absolute D Relative D (%)
Observer 1
Lumen CSA (mm2) 11.08±3.5 10.94±3.5 0.14±0.5 1.3
Lumen max. diameter (mm) 4.03±0.7 4.01±0.6 0.02±0.1 0.4
Lumen min. diameter (mm) 3.37±0.6 3.34±0.6 0.03±0.1 0.9
Lumen mean diameter (mm) 3.69±0.6 3.67±0.6 0.02±0.1 0.6
Lumen eccentricity 0.84±0.0 0.83±0.0 0.00±0.0 0.5
Vessel CSA (mm2) 17.40±4.0 17.46±4.0 0.07±0.4 0.4
Vessel max. diameter (mm) 4.92±0.6 4.93±0.6 0.01±0.1 0.3
Vessel min. diameter (mm) 4.36±0.6 4.37±0.6 0.01±0.1 0.2
Vessel mean diameter (mm) 4.63±0.6 4.64±0.6 0.01±0.0 0.2
Vessel eccentricity 0.89±0.0 0.89±0.0 0.00±0.0 0.1
Plaque CSA (mm2) 6.32±2.0 6.53±2.1 0.21±0.4 3.2
Plaque max. thickness (mm) 1.01±0.2 1.02±0.2 0.01±0.1 0.7
Plaque min. thickness (mm) 0.09±0.1 0.09±0.1 0.01±0.0 8.2
Plaque eccentricity (mm) 0.09±0.1 0.10±0.1 0.01±0.0 10.0
Plaque burden (%) 36.80±9.9 37.77±9.9 0.97±2.4 2.6
Observer 2
Lumen CSA (mm2) 10.66±3.8 10.67±3.8 0.01±0.4 0.1
Lumen max. diameter (mm) 3.90±0.7 3.91±0.7 0.01±0.1 0.2
Lumen min. diameter (mm) 3.34±0.6 3.33±0.6 0.01±0.1 0.3
Lumen mean diameter (mm) 3.61±0.6 3.61±0.7 0.00±0.1 0.0
Lumen eccentricity 0.86±0.0 0.85±0.0 0.01±0.0 0.6
Vessel CSA (mm2) 17.76±4.0 17.80±4.0 0.05±0.4 0.3
Vessel max. diameter (mm) 4.95±0.6 4.96±0.6 0.01±0.1 0.3
Vessel min. diameter (mm) 4.41±0.6 4.42±0.6 0.01±0.1 0.1
Vessel mean diameter (mm) 4.68±0.6 4.69±0.6 0.01±0.0 0.1
Vessel eccentricity 0.89±0.0 0.89±0.0 0.00±0.0 0.1
Plaque CSA (mm2) 7.10±2.1 7.13±2.2 0.03±0.4 0.5
Plaque max. thickness (mm) 1.05±0.2 1.04±0.3 0.00±0.1 0.2
Plaque min. thickness (mm) 0.16±0.1 0.16±0.1 0.01±0.0 4.7
Plaque eccentricity (mm) 0.16±0.1 0.17±0.1 0.01±0.0 6.7
Plaque burden (%) 40.75±10.7 40.93±11.2 0.19±1.8 0.5
LCSA, VCSA and PCSA refer to lumen, vessel and plaque CSAs. Plaque burden was calculated as [(EEMarea  Lumenarea=
EEMareaÞ  100].
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Table 3. Mean CSA compositional measurements of matched ROI with two subsequent 20 MHz IVUS imaging catheters (n:16).
Catheter 1 Catheter 2 Absolute D Relative D (%)
Observer 1
Calcium CSA (mm2) 0.17±0.3 0.16±0.2 0.01±0.1 8.0
Calcium (%) 4.27±5.2 3.82±3.8 0.45±2.6 11.1
Fibrous CSA (mm2) 1.96±1.0 2.11±1.1 0.16±0.4 7.7
Fibrous (%) 60.37±9.2 62.15±8.7 1.78±10.0 2.9
Fibrolipidic CSA (mm2) 0.66±0.4 0.63±0.3 0.02±0.3 3.5
Fibrolipidic (%) 21.10±9.8 19.58±7.0 1.53±8.3 7.5
Necrotic core CSA (mm2) 0.40±0.4 0.43±0.4 0.02±0.2 5.7
Necrotic core (%) 11.27±6.8 10.87±6.6 0.40±5.4 3.6
Observer 2
Calcium CSA (mm2) 0.17±0.3 0.16±0.2 0.01±0.1 8.7
Calcium (%) 4.08±5.0 3.74±3.4 0.34±2.4 8.7
Fibrous CSA (mm2) 2.21±1.1 2.28±1.2 0.07±0.4 3.1
Fibrous (%) 58.12±10.5 60.63±7.9 2.51±10.1 4.2
Fibrolipidic CSA (mm2) 0.88±0.6 0.77±0.4 0.11±0.4 13.1
Fibrolipidic (%) 22.97±11.7 20.95±10.8 2.01±9.6 9.2
Necrotic core CSA (mm2) 0.42±0.4 0.45±0.5 0.03±0.2 6.1
Necrotic core (%) 10.75±6.9 11.02±6.5 0.26±5.5 2.4
LCSA, VCSA and PCSA refer to lumen, vessel and plaque CSAs. Plaque burden was calculated as [(EEMarea  Lumenarea=
EEMareaÞ  100].
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 5 10 15 20
Mean Lumen CSA (mm2)
Di
ffe
re
n
ce
in
Lu
m
en
CS
A
be
tw
ee
n
ca
th
et
er
s
(m
m
2)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 5 10 15 20 25
Mean Vessel CSA (mm2) 
Di
ffe
re
n
ce
in
Ve
ss
el
CS
A
be
tw
ee
n
ca
th
et
er
s
(m
m
2)
-1,8
-1,3
-0,8
-0,3
0,2
0,7
1,2
1,7
0 2 4 6 8 10 12
Mean Plaque CSA (mm2)
Di
ffe
re
n
ce
in
Pl
aq
u
e
CS
A
be
tw
ee
n
ca
th
et
er
s
(m
m
2)
-10
-8
-6
-4
-2
0
2
4
6
8
10
0 10 20 30 40 50 60
Mean Plaque burden (%)
Di
ffe
re
n
ce
in
pl
aq
u
e
bu
rd
en
be
tw
ee
n
ca
th
et
er
s
(%
)
Figure 1. Bland–Altman plots depicting the (observer 1) agreement between catheters for geometrical measurements (n=16).
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eccentricity (54%). The largest relative difference
was found in fibrolipidic measurements (Table 4).
Narrow limits of agreement and few outliers
(Figures 3 and 4) were found between observers
both for geometrical (limits of agreement for lu-
men, vessel, plaque and plaque burden measure-
ments of 2.61, )2.09 mm2; 2.20–3.03 mm2; 1.70,
)3.04 mm2; and 9.16, )16.41%; respectively) and
compositional (limits of agreement for calcium,
fibrous, fibrolipidic and necrotic core measure-
ments of 0.08, )0.09 mm2; 0.89, )1.28 mm2; 0.74,
)1.06 mm2; and 0.16, )0.20 mm2; respectively)
measurements. It is noteworthy that the fibrous
and fibrolipidic CSA measurements were highly
accurate when assessing cross-sections with small
fibrous or fibrolipidic content (Figure 4).
Discussion
Over the past few years, IVUShas been employed as
a tool to assess the temporal effect of conventional
and novel drug therapies on coronary plaque size in
longitudinal studies [8, 20]. More recently, the dis-
cordance between the beneficial clinical effects of
secondary prevention strategies and their effect on
plaque volume had lead investigators to explore a
potential significant effect on plaque composition
[21].
Tissue characterization by means of IVUS ra-
diofrequency (RF) data analysis is a potential tool
to enable an accurate evaluation of the composition
of coronary plaques [13]. Several investigators have
explored the potential of RF data analysis in vivo
and reported promising findings [15–17, 22, 23].
This technique has the potential to detect temporal
changes in plaque composition and therefore stud-
ies have been conducted to assess the effect of con-
ventional drug therapies on the phenotype of
coronary atherosclerosis [18, 22, 23]. In addition,
there are currently several large trials being con-
ducted with the aim to assess the natural history of
high-risk plaques by means of this technique.
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Figure 2. Bland–Altman plots depicting the (observer 1) agreement between catheters for compositional measurements (n=16).
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As the impact of drug therapies on the athero-
sclerotic plaque burden and composition over time
is relatively small, highly reproducible IVUS-VH
measurements are essential. Despite such pivotal
need for reproducibility data to address the sta-
bility of the technique, such studies are lacking.
Only indirect evidence of reproducibility has been
reported such as a study conducted by our group
to assess the 6-month change in plaque composi-
tion with no controlled therapeutic intervention
[18], and the study conducted by Kawasaki et al.
who reported the intra and inter-observer vari-
ability of measurements performed using the same
pullback [22].
The present study has a unique characteristic
since we used two catheters of the same kind at the
same time-point, thus simulating the scenario of a
longitudinal study.
The main finding of the present study was that
IVUS-VH measurements had an acceptable
reproducibility. As expected, compositional mea-
surements were more variable than geometrical
measurements. Nevertheless, it is noteworthy that
inter-catheter differences were predominantly
lower than 10%, highly correlated and showed a
good agreement. Of note, necrotic core measure-
ments, probably the most relevant component of
coronary plaques and currently subject of intense
research, showed an excellent inter-catheter and
inter-observer agreement. This has a major
importance since the temporal change of such
component could potentially become an imaging
endpoint of longitudinal studies. Similarly, cal-
cium measurements, another important compo-
nent of atherosclerotic plaques, showed good
inter-catheter and inter-observer agreement. The
relatively high inter-observer variability of some
IVUS-VH variables raises some caution and
should be taken into consideration when
performing longitudinal studies analyzed by
Table 4. Geometrical and compositional measurements of matched CSAs between different observers (n:1316).
Observer 1 Observer 2 Absolute D Relative D (%)
Geometrical data
Lumen CSA (mm2) 10.83±3.8 10.51±4.0 0.26±1.2 2.5
Lumen max. diameter (mm) 3.96±0.7 3.86±0.8 0.08±0.4 2.1
Lumen min. diameter (mm) 3.34±0.6 3.31±0.7 0.01±0.3 0.2
Lumen mean diameter (mm) 3.65±0.7 3.58±0.7 0.04±0.3 1.1
Lumen eccentricity 0.84±0.1 0.86±0.1 0.02±0.1 2.3
Vessel CSA (mm2) 16.90±4.2 17.22±4.3 0.41±1.3 2.4
Vessel max. diameter (mm) 4.84±0.6 4.87±0.6 0.06±0.4 1.1
Vessel min. diameter (mm) 4.30±0.6 4.35±0.6 0.08±0.3 1.7
Vessel mean diameter (mm) 4.56±0.6 4.61±0.6 0.07±0.3 1.5
Vessel eccentricity 0.89±0.1 0.89±0.1 0.01±0.1 1.1
Plaque CSA (mm2) 6.07±2.3 6.72±2.3 0.67±1.2 10.3
Plaque max. thickness (mm) 0.96±0.3 1.01±0.3 0.03±0.2 3.4
Plaque min. thickness (mm) 0.09±0.1 0.16±0.1 0.07±0.1 53.3
Plaque eccentricity (mm) 0.09±0.1 0.16±0.1 0.07±0.1 53.6
Plaque burden (%) 36.62±12.2 40.07±12.5 3.63±6.4 9.5
Compositional data
Calcium CSA (mm2) 0.12±0.2 0.12±0.2 0.00±0.0 2.9
Calcium (%) 3.66±6.4 3.51±6.0 0.13±2.4 3.7
Fibrous CSA (mm2) 1.86±1.3 2.05±1.3 0.20±0.5 10.2
Fibrous (%) 61.48±18.2 60.05±18.2 1.10±14.3 1.8
Fibrolipidic CSA (mm2) 0.60±0.5 0.75±0.7 0.16±0.5 23.5
Fibrolipidic (%) 22.34±14.0 22.09±15.3 1.86±11.8 8.8
Necrotic core CSA (mm2) 0.35±0.4 0.37±0.4 0.02±0.1 6.3
Necrotic core (%) 10.45±10.1 10.22±9.8 0.17±5.7 1.6
LCSA, VCSA and PCSA refer to lumen, vessel and plaque CSAs. Plaque burden was calculated as [(EEMarea ) Lumenarea /EEMarea)
100].
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Figure 3. Bland–Altman plots showing the inter-observer agreement for geometrical measurements (n=1316).
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Figure 4. Bland–Altman plots showing the inter-observer agreement for compositional measurements (n=1316).
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core laboratories. Overall, the inter-catheter and
inter-observer differences shown might provide
boundaries over which changes are statistically
significant.
It is evident yet worth mentioning that precise
contour detection probably has an essential role in
the reproducibility of IVUS-VH measurements.
The inter-observer relative difference in plaque
CSA measurements was 10%, the commonly ac-
cepted threshold. This gives an additive value to
our study, since it provides a ‘‘real-world’’ scenario
that can aid investigators to perform precise power
calculations for longitudinal studies.
Finally, although we aimed at studying non-
tortuous and non-severely calcified vessels,
phased-array IVUS imaging catheters are devoid
from a covering sheath and pullbacks are therefore
occasionally prone to be non-uniform. This clearly
has an impact on determination of the size and
composition of atherosclerotic plaques and needs
to be taken into consideration for the design of
longitudinal studies (Figure 5).
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Figure 5. Sequential plotting of a matched ROI interrogated with two catheters. The mean CSA (y axis) of each plaque component is
colour-coded (calcium: white, fibrous: green, fibrolipidic: greenish-yellow and necrotic core: red). This figure shows an example of the
impact of non-uniform pullbacks on geometrical and compositional measurements.
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Limitations
The studied population was relatively small. Nev-
ertheless, the conductance of large in vivo studies
of this nature is complicated due to obvious ethical
issues. The selection of a population of patients
with non-tortuous and non-severely calcified ves-
sels was driven by the aim to study the reproduc-
ibility of the technique itself, not of the pullback
device. Nevertheless, as shown in Figure 5, the
impact of non-uniform pullback speed was not
negligible potentially influencing the results.
Conclusions
The present study demonstrates that the geomet-
rical and compositional output of IVUS-VH is
acceptably reproducible. In addition, by providing
a ‘‘real-world’’ scenario, this study can aid inves-
tigators to perform precise power calculations for
longitudinal studies.
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